Overview:
Diabetes Profile-1Introduction: The Diabetes Panel 1 Profile is a diagnostic tool designed to conduct basic diabetes screening using serum and urine samples. Associated with conditions like type 2 diabetes and prediabetes, these disorders present with polydipsia, fatigue, and severe complications if untreated, particularly in individuals with metabolic concerns. Per the 2023 Biochemistry and Clinical Pathology guidelines, the test employs biochemistry and clinical pathology with spectrophotometry and microscopy technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for diabetes screening in clinical settings. This diagnostic falls under diabetes screening and targets individuals with suspected diabetes, addressing the challenge of accurate parameter assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its dual-sample approach ensures reliable detection.
Other Names: Diabetes 1 Pfl.
FDA Status: FDA approved, CLIA certified for biochemistry and clinical pathology, compliant with 2025 standards.
Historical Milestone: Introduced in the 1980s by metabolic labs, this test advanced basic diabetes diagnostics.
Purpose: The test screens for 11 parameters including fasting glucose to guide diabetes assessment, assess glycemic control and renal function, and inform treatment and prevention strategies.
Test Parameters: 1. Fasting Glucose, 2. HbA1c, 3. Creatinine, 4. Urea, 5. Urine Glucose, 6. Urine Microalbumin, 7. Urine Albumin/Creatinine Ratio, 8. Total Cholesterol, 9. HDL, 10. LDL, 11. Triglycerides.
Pretest Condition: Fasting 10-12 hours required; patients should report polydipsia, fatigue, or recent metabolic symptoms.
Specimen: 3 mL serum in 1 SST, 10 mL urine in 1 sterile container, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours (Serum), 24 hours (Urine) with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days (Serum, Urine) at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months (Serum, Urine) at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on polydipsia, fatigue, prior diabetes reactions, or family history of metabolic disorders, as well as any recent trauma or treatments.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated diabetes including neuropathy, benefits of early detection, and minimal discomfort from sample collection.
Procedural Considerations: The test involves sample processing using spectrophotometry and microscopy and interpret results within 1-2 days using provided controls.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent food intake can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal results indicate possible diabetes, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in early disease stages.
Specialist Consultation: General practitioners or specialists in endocrinology should be consulted for case management, treatment planning, and coordination with health programs.
Additional Supporting Tests: Oral glucose tolerance test or C-peptide for confirmation.
Test Limitations: The test may produce false negatives in early disease stages or false positives in acute illness, requiring a comprehensive diagnostic approach that includes clinical correlation.
References: Biochemistry and Clinical Pathology Guidelines 2023, Journal of Diabetes Research 2024, Chemistry 2025.
